Shopping Cart 0
Cart Subtotal
USD 0

Mitsubishi Tanabe Pharma Corp (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe's major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp (4508)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 22

Venture Financing 22

QurAlis Raises Funds through Seed Financing 22

Ribometrix Raises USD7.5 Million in Seed Financing 23

Forge Therapeutics Raises USD15 million in Series A Financing 24

Rigontec Raises Additional USD16.7 Million in Series A Financing 25

miRagen Therapeutics Raises USD41 Million in Series C Financing 27

Thrasos Therapeutics Raises USD21 Million in Series D Financing 29

NeuroDerm Raises USD16 Million in Venture Financing 31

Covagen Raises USD 50.3 Million In Series B Financing 32

F-Star Alpha Raises USD 13 Million In Series A Financing 34

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 35

Genocea Biosciences Raises USD 30 Million In Series C Financing 37

GenKyoTex Raises USD 26 Million In Extended Series C Financing 39

Partnerships 41

Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41

Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42

Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43

AvantGen Partners with Tanabe Research Laboratories USA 44

Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46

Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55

Medicago Enters into Contract with Public Health Agency of Canada 56

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59

Medicago Enters into Agreement with University of Cape Town 60

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65

Medicago Enters Into Co-Development Agreement With Cellectis 66

Licensing Agreements 67

Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67

Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81

Equity Offering 82

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84

NeuroDerm Raises USD77 Million in Public Offering of Shares 86

NeuroDerm Raises USD45 Million in IPO 88

Medicago Announces Private Placement Of Common Stock For USD 3.4 Million 90

Asset Transactions 91

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91

Acquisition 92

Mitsubishi Tanabe Pharma Acquires Stelic Institute 92

Merck Acquires Rigontec 93

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95

Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For USD 172 Million In Going Private Transaction 99

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 101

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103

Shire Completes Acquisition of Ferrokin Biosciences For Up To USD 320 Million 104

Mitsubishi Tanabe Pharma Corp-Key Competitors 106

Mitsubishi Tanabe Pharma Corp-Key Employees 107

Mitsubishi Tanabe Pharma Corp-Locations And Subsidiaries 108

Head Office 108

Other Locations & Subsidiaries 108

Joint Venture 110

Recent Developments 112

Strategy And Business Planning 112

Sep 29, 2017: Mitsubishi Tanabe Pharma: Organizational Change and Personnel Change 112

Financial Announcements 113

Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 113

May 10, 2017: Mitsubishi Tanabe Pharma Reports Revenue Of JPY424 Billion In Fiscal 2017 115

Corporate Communications 116

Sep 28, 2018: New country manager brings significant business leadership and healthcare expertise to Mitsubishi Tanabe Pharma Canada 116

Government and Public Interest 117

Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 117

May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 118

Product News 119

11/30/2017: Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA (edaravone) to U.S. Department of Veterans Affairs National Formulary 119

11/16/2017: Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available 120

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 121

08/11/2017: Allegheny General Hospital Patient Among First in U.S. to Receive New Drug for Treatment of ALS 122

08/08/2017: First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S. 123

07/25/2017: MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA 124

06/30/2017: MT Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients 125

06/20/2017: Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court 126

05/18/2017: MT Pharma America Presents 12-Month RADICAVA (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting 127

05/16/2017: Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS 128

05/05/2017: MT Pharma America Announces FDA Approval of RADICAVA (Edaravone), the First New Treatment Option for ALS in More Than 20 Years 129

04/24/2017: Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS 130

04/18/2018: Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting 132

02/21/2017: Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia 133

Product Approvals 134

May 28, 2018: EMA accepts our filing for Edaravone to treat ALS 134

Apr 10, 2018: Health Canada Accepts Mitsubishi Tanabe Pharma's NDS Filing for Edaravone to Treat ALS 135

Jan 23, 2018: Swissmedic accepts our filing for Edaravone to treat ALS 136

Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS 137

Clinical Trials 138

Jun 21, 2018: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting 138

Apr 09, 2018: Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder 139

Dec 19, 2017: Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia 140

Dec 05, 2017: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (Edaravone) At 28th International Symposium on ALS/MND in Boston 141

Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a 142

Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS 144

Sep 07, 2017: Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal 145

Sep 05, 2017: Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS 146

Jul 31, 2017: American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia 148

Jun 22, 2017: Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia 149

May 15, 2017: Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA 150

May 15, 2017: Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 151

Apr 20, 2017: MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting 153

Jan 20, 2017: Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function 154

Other Significant Developments 155

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 155

Sep 26, 2018: Mitsubishi Tanabe Pharma announce company name changes of our oversea subsidiaries 156

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science 157

Mar 06, 2018: Mitsubishi Tanabe Pharma Announces Singapore Subsidiary Name Change 158

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma Strengthening business development in the ASEAN region 159

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region 160

Appendix 161

Methodology 161

About GlobalData 161

Contact Us 161

Disclaimer 161


List Of Figure

List of Figures

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

QurAlis Raises Funds through Seed Financing 22

Ribometrix Raises USD7.5 Million in Seed Financing 23

Forge Therapeutics Raises USD15 million in Series A Financing 24

Rigontec Raises Additional USD16.7 Million in Series A Financing 25

miRagen Therapeutics Raises USD41 Million in Series C Financing 27

Thrasos Therapeutics Raises USD21 Million in Series D Financing 29

NeuroDerm Raises USD16 Million in Venture Financing 31

Covagen Raises USD 50.3 Million In Series B Financing 32

F-Star Alpha Raises USD 13 Million In Series A Financing 34

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 35

Genocea Biosciences Raises USD 30 Million In Series C Financing 37

GenKyoTex Raises USD 26 Million In Extended Series C Financing 39

Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41

Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42

Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43

AvantGen Partners with Tanabe Research Laboratories USA 44

Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46

Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55

Medicago Enters into Contract with Public Health Agency of Canada 56

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59

Medicago Enters into Agreement with University of Cape Town 60

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65

Medicago Enters Into Co-Development Agreement With Cellectis 66

Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67

Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84

NeuroDerm Raises USD77 Million in Public Offering of Shares 86

NeuroDerm Raises USD45 Million in IPO 88

Medicago Announces Private Placement Of Common Stock For USD 3.4 Million 90

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91

Mitsubishi Tanabe Pharma Acquires Stelic Institute 92

Merck Acquires Rigontec 93

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95

Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For USD 172 Million In Going Private Transaction 99

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 101

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103

Shire Completes Acquisition of Ferrokin Biosciences For Up To USD 320 Million 104

Mitsubishi Tanabe Pharma Corp, Key Competitors 106

Mitsubishi Tanabe Pharma Corp, Key Employees 107

Mitsubishi Tanabe Pharma Corp, Other Locations 108

Mitsubishi Tanabe Pharma Corp, Subsidiaries 109

Mitsubishi Tanabe Pharma Corp, Joint Venture 110

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Mitsubishi Tanabe Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe's major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp (4508)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 22

Venture Financing 22

QurAlis Raises Funds through Seed Financing 22

Ribometrix Raises USD7.5 Million in Seed Financing 23

Forge Therapeutics Raises USD15 million in Series A Financing 24

Rigontec Raises Additional USD16.7 Million in Series A Financing 25

miRagen Therapeutics Raises USD41 Million in Series C Financing 27

Thrasos Therapeutics Raises USD21 Million in Series D Financing 29

NeuroDerm Raises USD16 Million in Venture Financing 31

Covagen Raises USD 50.3 Million In Series B Financing 32

F-Star Alpha Raises USD 13 Million In Series A Financing 34

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 35

Genocea Biosciences Raises USD 30 Million In Series C Financing 37

GenKyoTex Raises USD 26 Million In Extended Series C Financing 39

Partnerships 41

Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41

Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42

Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43

AvantGen Partners with Tanabe Research Laboratories USA 44

Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46

Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55

Medicago Enters into Contract with Public Health Agency of Canada 56

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59

Medicago Enters into Agreement with University of Cape Town 60

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65

Medicago Enters Into Co-Development Agreement With Cellectis 66

Licensing Agreements 67

Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67

Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81

Equity Offering 82

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84

NeuroDerm Raises USD77 Million in Public Offering of Shares 86

NeuroDerm Raises USD45 Million in IPO 88

Medicago Announces Private Placement Of Common Stock For USD 3.4 Million 90

Asset Transactions 91

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91

Acquisition 92

Mitsubishi Tanabe Pharma Acquires Stelic Institute 92

Merck Acquires Rigontec 93

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95

Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For USD 172 Million In Going Private Transaction 99

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 101

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103

Shire Completes Acquisition of Ferrokin Biosciences For Up To USD 320 Million 104

Mitsubishi Tanabe Pharma Corp-Key Competitors 106

Mitsubishi Tanabe Pharma Corp-Key Employees 107

Mitsubishi Tanabe Pharma Corp-Locations And Subsidiaries 108

Head Office 108

Other Locations & Subsidiaries 108

Joint Venture 110

Recent Developments 112

Strategy And Business Planning 112

Sep 29, 2017: Mitsubishi Tanabe Pharma: Organizational Change and Personnel Change 112

Financial Announcements 113

Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 113

May 10, 2017: Mitsubishi Tanabe Pharma Reports Revenue Of JPY424 Billion In Fiscal 2017 115

Corporate Communications 116

Sep 28, 2018: New country manager brings significant business leadership and healthcare expertise to Mitsubishi Tanabe Pharma Canada 116

Government and Public Interest 117

Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 117

May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 118

Product News 119

11/30/2017: Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA (edaravone) to U.S. Department of Veterans Affairs National Formulary 119

11/16/2017: Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available 120

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 121

08/11/2017: Allegheny General Hospital Patient Among First in U.S. to Receive New Drug for Treatment of ALS 122

08/08/2017: First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S. 123

07/25/2017: MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA 124

06/30/2017: MT Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients 125

06/20/2017: Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court 126

05/18/2017: MT Pharma America Presents 12-Month RADICAVA (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting 127

05/16/2017: Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS 128

05/05/2017: MT Pharma America Announces FDA Approval of RADICAVA (Edaravone), the First New Treatment Option for ALS in More Than 20 Years 129

04/24/2017: Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS 130

04/18/2018: Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting 132

02/21/2017: Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia 133

Product Approvals 134

May 28, 2018: EMA accepts our filing for Edaravone to treat ALS 134

Apr 10, 2018: Health Canada Accepts Mitsubishi Tanabe Pharma's NDS Filing for Edaravone to Treat ALS 135

Jan 23, 2018: Swissmedic accepts our filing for Edaravone to treat ALS 136

Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS 137

Clinical Trials 138

Jun 21, 2018: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting 138

Apr 09, 2018: Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder 139

Dec 19, 2017: Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia 140

Dec 05, 2017: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (Edaravone) At 28th International Symposium on ALS/MND in Boston 141

Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a 142

Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS 144

Sep 07, 2017: Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal 145

Sep 05, 2017: Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS 146

Jul 31, 2017: American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia 148

Jun 22, 2017: Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia 149

May 15, 2017: Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA 150

May 15, 2017: Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 151

Apr 20, 2017: MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting 153

Jan 20, 2017: Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function 154

Other Significant Developments 155

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 155

Sep 26, 2018: Mitsubishi Tanabe Pharma announce company name changes of our oversea subsidiaries 156

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science 157

Mar 06, 2018: Mitsubishi Tanabe Pharma Announces Singapore Subsidiary Name Change 158

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma Strengthening business development in the ASEAN region 159

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region 160

Appendix 161

Methodology 161

About GlobalData 161

Contact Us 161

Disclaimer 161


List Of Figure

List of Figures

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14


List Of Table

List of Tables

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Mitsubishi Tanabe Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 12

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15

QurAlis Raises Funds through Seed Financing 22

Ribometrix Raises USD7.5 Million in Seed Financing 23

Forge Therapeutics Raises USD15 million in Series A Financing 24

Rigontec Raises Additional USD16.7 Million in Series A Financing 25

miRagen Therapeutics Raises USD41 Million in Series C Financing 27

Thrasos Therapeutics Raises USD21 Million in Series D Financing 29

NeuroDerm Raises USD16 Million in Venture Financing 31

Covagen Raises USD 50.3 Million In Series B Financing 32

F-Star Alpha Raises USD 13 Million In Series A Financing 34

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 35

Genocea Biosciences Raises USD 30 Million In Series C Financing 37

GenKyoTex Raises USD 26 Million In Extended Series C Financing 39

Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41

Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42

Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43

AvantGen Partners with Tanabe Research Laboratories USA 44

Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46

Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47

Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55

Medicago Enters into Contract with Public Health Agency of Canada 56

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59

Medicago Enters into Agreement with University of Cape Town 60

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65

Medicago Enters Into Co-Development Agreement With Cellectis 66

Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67

Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84

NeuroDerm Raises USD77 Million in Public Offering of Shares 86

NeuroDerm Raises USD45 Million in IPO 88

Medicago Announces Private Placement Of Common Stock For USD 3.4 Million 90

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91

Mitsubishi Tanabe Pharma Acquires Stelic Institute 92

Merck Acquires Rigontec 93

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95

Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For USD 172 Million In Going Private Transaction 99

Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 101

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103

Shire Completes Acquisition of Ferrokin Biosciences For Up To USD 320 Million 104

Mitsubishi Tanabe Pharma Corp, Key Competitors 106

Mitsubishi Tanabe Pharma Corp, Key Employees 107

Mitsubishi Tanabe Pharma Corp, Other Locations 108

Mitsubishi Tanabe Pharma Corp, Subsidiaries 109

Mitsubishi Tanabe Pharma Corp, Joint Venture 110

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Mitsubishi Tanabe Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.